ORIGINAL RESEARCH ARTICLE ORIGINAL RESEARCH ARTICLE BACKGROUND: Pathological cardiac hypertrophy induced by stresses such as aging and neurohumoral activation is an independent risk factor for heart failure and is considered a target for the treatment of heart failure. However, the mechanisms underlying pathological cardiac hypertrophy remain largely unknown. We aimed to investigate the roles of SIRT2 in aging-related and angiotensin II (Ang II)-induced pathological cardiac hypertrophy.
H
eart failure is a growing public health problem and a leading cause of morbidity and mortality in modern society. Pathological cardiac hypertrophy induced by aging and neurohumoral activation (eg, angiotensin II [Ang II]) is an independent risk factor for heart failure. 1, 2 Antiaging strategies, such as caloric restriction, show cardiac benefits in rodents, monkeys, and humans. [3] [4] [5] Clinically, neurohormone-blocking drugs (including adrenergic receptor blockers, inhibitors of angiotensin-converting enzyme, and blockers of the Ang II receptor AT1) are commonly used to treat pathological hypertrophy and heart failure. 6 Defects in myocardial metabolism appear to be a major contributor to aging-related and stress-induced cardiac hypertrophy and subsequent heart failure. 7 Aging and aging-related cardiac hypertrophy are regulated by several core metabolic sensors, including AMP-activated protein kinase (AMPK), SIRT1, mammalian target of rapamycin (mTOR), and IGF1R (insulin-like growth factor 1 receptor). 8 For instance, AMPK is a major regulatory kinase that directly controls numerous metabolic processes, including fatty acid oxidation and glycolysis. AMPK can also regulate other metabolic pathways, such as the SIRT1, mTOR, and peroxisome proliferator-activated receptor gamma coactivator-1 alpha pathways.
9,10 AMPK contains 1 catalytic subunit (α) and 2 regulatory subunits (β and γ). Mutations in the AMPKγ subunit cause hypertrophic cardiomyopathy in humans. 9 AMPK deficiency contributes to cardiac hypertrophy induced by aging, neurohumoral activation, pressure overload, and myocardial infarction. 9, 11 Activation of AMPK by AICAR (5-Aminoimidazole-4-carboxamide 1-β-D-ribofuranoside Acadesine N1-(β-D-Ribofuranosyl)-5-aminoimidazole-4-carboxamide) or metformin protects the heart from cardiac hypertrophy induced by aging and other stresses. 12, 13 The Sirtuin family of proteins is a family of class III nicotinamide adenine dinucleotide-dependent deacetylase that deacetylates histone and nonhistone proteins. Sirtuins regulate metabolism and aging-related diseases, including diabetes mellitus and cardiovascular diseases. [14] [15] [16] Among the Sirtuins, the cytosol member SIRT2 is less characterized. SIRT2 is expressed in a wide range of tissues, particularly in metabolically relevant tissues, such as the heart, brain, and adipose tissue. 17 SIRT2 plays essential roles in diverse aspects of metabolism. 17 However, the pivotal target of SIRT2 in metabolic processes and the roles of SIRT2 in pathological cardiac hypertrophy remain unknown.
In the present study, we demonstrate that SIRT2 represses aging-related and stress-induced cardiac hypertrophy, at least in part, by maintaining signaling through the liver kinase B1 (LKB1)-AMPK pathway, the central pathway controlling various aspects of metabolism. We found that SIRT2 protein levels were reduced in the hearts of aged and Ang II-infused mice. Sirt2 knockout (Sirt2-KO) promoted aging-related and Ang II-induced cardiac hypertrophy and fibrosis and caused cardiac dysfunction, whereas cardiac-specific SIRT2 overexpression inhibited Ang II-induced cardiac hypertrophy and rescued cardiac function. Moreover, we showed that SIRT2 bound to and deacetylated LKB1, which activated the LKB1-AMPK signaling pathway in the hearts of aged mice and Ang II-infused mice. Additionally, Sirt2-KO attenuated metformin-induced activation of AMPK signaling and, subsequently, the cardioprotective functions of metformin in Ang II-induced hypertrophic hearts.
METHODS

KO and Transgenic Mice
All animal protocols were approved by the Animal Care and Use Committee at the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, and Peking Union Medical College. Global germ-line Sirt2-KO mice (C57BL/6J background; stock no. 012772) were purchased from Jackson Laboratories. Transgenic mice with cardiomyocyte-specific SIRT2 overexpression were generated as previously described. 18 An expanded method for generation of transgenic mice is available in the Methods in the online-only Data Supplement.
Cardiac Hypertrophy Model and Metformin Treatment
The young (4-month-old) and aged (24-month-old) wildtype (WT) and Sirt2-KO mice were subjected to pathological analysis of cardiac hypertrophy. Cardiac hypertrophy was also induced in 8-to ≈12-week-old mice by chronic subcutaneous
Clinical Perspective
What Is New?
• For the first time, we demonstrate that SIRT2 protein level and activity are reduced during pathological cardiac hypertrophy, and SIRT2 deficiency promotes aging-and angiotensin II-induced pathological cardiac hypertrophy, whereas SIRT2 overexpression represses pathological cardiac hypertrophy.
• SIRT2 deacetylates liver kinase B1 at lysine 48 to activate the liver kinase B1-AMP-activated protein kinase signaling and prevents hypertrophy of cardiomyocytes.
• SIRT2 is critically involved in metformin-mediated activation of AMP-activated protein kinase and cardioprotective effects.
What Are the Clinical Implications?
• We identify SIRT2 as a novel target for the treatment of pathological cardiac hypertrophy induced by aging and other pathological stress.
• Our study suggests that SIRT2 may be essential for the beneficial effects of metformin against pathological cardiac hypertrophy.
SIRT2 Prevents Cardiac Hypertrophy
Circulation. 
Histological Analysis
For histological analysis, hearts were arrested with a 10% potassium chloride solution at end diastole and then fixed in 4% paraformaldehyde. Fixed hearts were embedded in paraffin and cut transversely into 5-µm sections. Serial heart sections were stained with hematoxylin-eosin or wheat germ agglutinin (no. W11261; Invitrogen) to measure myocyte cross-sectional areas. The degree of collagen deposition was detected by a Picrosirius red staining kit (no. ab150681; Abcam). Images were analyzed using a quantitative digital image analysis system (Image-Pro Plus 6.0).
Statistical Analysis
All experiments were performed at least in triplicate unless otherwise stated. 
RESULTS
SIRT2 Deficiency Aggravates Cardiac Hypertrophy in Aged Mice
To investigate the role of SIRT2 in aging-related cardiac hypertrophy, the male Sirt2-KO mice ( Figure IA and B in the online-only Data Supplement) and their control WT littermates were maintained for 2 years. The body weights of WT and Sirt2-KO mice were comparable at 4 and 24 months ( Figure II in the online-only Data Supplement). Remarkably, aged Sirt2-KO mice showed more visible aging characteristics (eg, hair browning) than their WT littermates ( Figure 1A ), indicating that Sirt2-KO might affect the health of aged mice. Young (4-month-old) and aged (24-month-old) mice were subjected to functional cardiac phenotyping. Significantly, Sirt2-KO caused echocardiography-detectable dysfunction in aged mice, as evidenced by decreases in cardiac ejection fraction and fractional shortening ( Figure 1B) . However, Sirt2 deficiency did not affect heart rate, systolic blood pressure, or diastolic blood pressure in aged mice ( Figure IIB and C in the online-only Data Supplement). The aged WT mice had an increased heart weight-to-tibia length ratio compared with those of young mice, and heart weight-to-tibia length ratio was further enhanced in aged Sirt2-KO mice ( Figure 1C ). The heart weight-tobody weight ratio was also increased in aged Sirt2-KO mice compared with that in aged WT mice ( Figure IID in the online-only Data Supplement). Next, hematoxylineosin, wheat germ agglutinin, and Picrosirius red staining were performed to analyze cardiac hypertrophy and fibrosis. The results showed that hypertrophic remodeling and fibrosis of the myocardial tissues were significant in aged WT mice compared with those in young WT mice. It is important to note that these abnormalities were enhanced in the hearts of aged Sirt2-KO mice compared with aged WT mice ( Figure 1D and E). Hypertrophic remodeling and heart failure commonly lead to pulmonary remodeling. Indeed, Sirt2-KO increased body weight-and tibia lengthnormalized lung weights in aged mice ( Figure IIE in the online-only Data Supplement), which is a sign of pulmonary congestion because of abnormal cardiac function.
Aging-dependent cardiac hypertrophy is regulated by several central metabolic regulators, including AMPK, SIRT1, mTOR, and IGF1R. 12, [19] [20] [21] Therefore, these core metabolic regulators were analyzed in the hearts of aged WT and Sirt2-KO mice. IGF1R phosphorylation at Tyr1135 and SIRT1 expression were comparable in the hearts of aged WT and Sirt2-KO mice. AMPK phosphorylation at Thr172 was significantly reduced, whereas mTOR phosphorylation at Ser2448, a negative downstream of AMPK, 10 was increased in aged Sirt2-KO hearts compared with aged WT hearts ( Figure 1F ). These findings implicate that AMPK might be involved in the effect of SIRT2 on aging-related cardiac hypertrophy.
SIRT2 Expression and Activity Are Reduced During Cardiac Hypertrophy
To explore the potential functions of SIRT2 during cardiac hypertrophy induced by aging as described earlier (SIRT2 Deficiency Aggravates Cardiac Hypertrophy in Aged Mice) and by other stresses, the expression and activity levels of SIRT2 were examined in aged and hypertrophic mouse hearts. SIRT2 protein levels were significantly downregulated in aged (24-month-old) hearts compared with young (4-month-old) hearts (Figure 2A ). The concentration of Ang II is upregulated in aged hearts, and activation of the renin-angiotensin system is one of the core mechanisms underlying cardiac aging in rodents. 22 Chronic infusion of Ang II recurs the development of cardiac hypertrophy observed in aged mice. 18 Therefore, cardiac hypertrophy Supplement). SIRT2 protein levels were decreased in Ang II-induced hypertrophic hearts ( Figure 2A ). Tubulin is a substrate of the deacetylase SIRT2. 23 The level of acetylated Tubulin at lysine 40 was upregulated in aged and Ang II-induced hypertrophic hearts ( Figure 2B ), indicating that SIRT2 activity was decreased in hypertrophic hearts. Consistently, the enzymatic activity assay also demonstrated that SIRT2 activity was decreased in Ang II-induced hypertrophic hearts ( Figure 2C ).
However, Sirt2 mRNA levels were not changed in aged or Ang II-induced cardiac hypertrophy ( Figure IIIB in the online-only Data Supplement), indicating that the protein stability might be decreased in hypertrophic hearts. The kinase c-Src can promote phosphorylation of SIRT2 to reduce the protein stability and inactivate SIRT2. 24 It is important to note that c-Src can be activated by various hypertrophic stresses (eg, Ang II) and accelerates the development of cardiac hypertrophy. 25 Indeed, c-Src was activated in aging and Ang II-induced hypertrophic hearts as well as Ang II-treated neonatal rat cardiomyocytes (NRCMs) ( Figure 2D and E). Strictly, inhibition of c-Src with its inhibitor SU6656 (5 μM) blocked an Ang II-induced decrease in the SIRT2 protein level in NRCMs ( Figure 2E ). Therefore, the decrease in SIRT2 protein level is at least in part mediated by cSrc activation during cardiac hypertrophy.
Sirt2-KO Aggravates Ang II-Induced Cardiac Hypertrophy
To test whether SIRT2 deficiency contributes to maladaptive hypertrophy and heart remodeling in vivo, 
Sirt2-KO mice and their WT littermates (8 to ≈12
weeks old) were exposed to sustained Ang II treatment for 4 weeks. When subjected to Ang II treatment, WT mice developed cardiac hypertrophy, as evidenced by decreased ejection fraction and fractional shortening and increased heart weight-to-body weight and heart weight-to-tibia length ratios ( Figure 3A and B). The hematoxylin-eosin and wheat germ agglutinin staining results also demonstrated that Ang II treatment increased cardiomyocyte size in WT mice ( Figure 3C ). Remarkably, these hypertrophic features were enhanced in the hearts of Sirt2-KO mice treated with Ang II (FigFigure 3 . Sirt2-KO aggravates Ang II-induced cardiac hypertrophy. A, Ejection fraction and fractional shortening of WT and Sirt2-KO mice treated with saline or Ang II (1.3 mg/kg/d) for 4 weeks (n=17 to ≈20). *P<0.05; **P<0.01; ***P<0.001. B, Heart weight-to-body weight (HW/BW) and heart weight-to-tibia length (HW/TL) ratios of WT and Sirt2-KO mice treated with saline or Ang II (n=16 to ≈20 ure 3A-C). Sirt2 deficiency also aggravated perivascular and interstitial fibrosis in the hypertrophic hearts ( Figure 3D) . Consistently, the quantitative real-time polymerase chain reaction results showed that these hypertrophic pathological phenotypes were accompanied by the upregulation of hypertrophic genes, including Anp (atrial natriuretic polypeptide), Bnp (brain natriuretic peptide), β-Mhc (myosin heavy chain β), Acta1 (α-sarcomeric actin), IL-6 (interleukin 6), and Rcan1.4 (regulator of calcineurin 1.4) , and fibrotic genes, including Ctgf (connective tissue growth factor), Col1a1 (collagen1a1), and Col3a1 (collagen3a1) ( Figure 3E ). The effects of Sirt2-KO on heart rate and blood pressure were examined. Neither Ang II treatment nor Sirt2-KO affected the heart rate of the mice. Ang II treatment increased the systolic and diastolic blood pressures of the mice, whereas they were not affected by Sirt2 deficiency ( Figure IVA and B in the online-only Data Supplement).
SIRT2 Overexpression Represses Ang II-Induced Cardiac Hypertrophy
We next investigated whether SIRT2 directly regulates cardiomyocyte hypertrophy using an in vitro model of cardiomyocyte hypertrophy induced by Ang II (1 μM Ang II treatment for 48 hours) in NRCMs. NRCMs were treated with AGK2 (10 μM), which specifically inhibited the activity of SIRT2 ( Figure VA and B in the online-only Data Supplement). 26 SIRT2 inhibition with AGK2 promoted an Ang II-induced increase in cardiomyocyte size and facilitated the expression of hypertrophic marker genes (Anp, Bnp, and β-Mhc) ( Figure 4A and B). Next, SIRT2 was overexpressed in NRCMs with adenovirus to investigate whether SIRT2 overexpression could repress Ang II-induced hypertrophy in NRCMs ( Figure VC in the online-only Data Supplement). NRCMs with SIRT2 overexpression had a dampened hypertrophic response to Ang II treatment based on the analysis of cardiomyocyte size and the expression levels of Anp, Bnp, and β-Mhc ( Figure 4C and D) .
We further evaluated whether SIRT2 overexpression in cardiomyocytes could rescue cardiac function in vivo. To this end, we generated 2 lines of cardiacspecific SIRT2-Tg mice that express human SIRT2 under the control of the mouse α-Mhc ( significant differences were found between these 2 lines of transgenic mice. Therefore, we used 1 SIRT2-Tg mouse line (SIRT2-Tg1) for further studies. The male C57BL/6J SIRT2-Tg mice and their non-Tg littermates (8 to ≈12 weeks old) were infused with Ang II for 4 weeks to induce cardiac hypertrophy. Cardiac-specific SIRT2 overexpression rescued the Ang II-induced decreases in ejection fraction and fractional shortening ( Figure 5A ) and inhibited the Ang II-induced increase in heart weights ( Figure 5B ). Furthermore, Ang II-mediated increases in cardiomyocyte size and cardiac fibrosis were significantly reduced in SIRT2-Tg mice ( Figure 5C and D) . In addition, the expression of hypertrophic and fibrotic genes was also reduced in the hypertrophic hearts of SIRT2-Tg mice ( Figure 5E ). Similar to the previous results in aged mice and Ang II-infused mice with Sirt2 deficiency, SIRT2 overexpression did not change heart rate, systolic blood pressure, or diastolic blood pressure ( Figure VIIA and B in the online-only Data Supplement).
Collectively, SIRT2 in cardiomyocytes represses hypertrophy directly, and cardiac-specific SIRT2 overexpression inhibits Ang II-induced cardiac hypertrophy and rescues cardiac function.
SIRT2 Maintains AMPK Signaling in Hypertrophic Hearts
Among the various metabolic sensors analyzed, we observed that AMPK signaling was repressed in aged Sirt2-KO hearts compared with aged WT hearts ( Figure 1F ). The metabolic orchestrator AMPK controls diverse aspects of cardiac metabolism, including glycolysis, fatty acid metabolism, protein synthesis, and autophagy. AMPK deficiency contributes to aging-dependent or stress-induced cardiac hypertrophy.
9,12 Therefore, we analyzed whether the defect in AMPK signaling might underlie the cardiac phenotype of SIRT2-modified mice on Ang II infusion. The phosphorylation of AMPK and its downstream substrates acetyl-CoA carboxylase (ACC) and regulatory-associated protein of mTOR were analyzed. In Ang II-induced hypertrophic hearts, Sirt2-KO hearts had substantially decreased AMPK pathway activation, including downregulation of AMPK phosphorylation at Thr172, ACC phosphorylation at Ser79, and regulatory-associated protein of mTOR phosphorylation at Ser792 ( Figure 6A ). In contrast, the AMPK signaling pathway was enhanced by SIRT2 overexpression in Ang II-induced hypertrophic hearts ( Figure 6A ). Similar results were observed in NRCMs because inhibition of SIRT2 activity with AGK2 reduced AMPK, ACC, and regulatory-associated protein of mTOR phosphorylation, whereas SIRT2 overexpression promoted the activation of AMPK signaling ( Figure 6B ). Next, we analyzed whether SIRT2-mediated AMPK activation contributes to the effect of SIRT2 on cardiomyocyte hypertrophy. In Ang II-induced hypertrophic cardiomyocytes, treatment with AMPK inhibitor compound C (10 μM) increased cardiomyocyte size and the expression of hypertrophic genes (Anp, Bnp, and β-Mhc). Notably, AMPK inhibition blocked the protective function of SIRT2 in Ang II-induced cardiomyocyte hypertrophy because the cardiomyocyte size and gene expression pattern were not affected by SIRT2 overexpression in NRCMs in the presence of compound C (Figure 6C and D) . SIRT2 maintains the activation of AMPK signaling, which in turn contributes to the protective function of SIRT2 during cardiomyocyte hypertrophy.
Deacetylation of LKB1 Is Involved in SIRT2-Mediated Activation of AMPK
A previous report showed that the acetylation of AMPKα1 and α2 could repress AMPK phosphorylation. 27 Therefore, we analyzed the effects of SIRT2 on the acetylation of these 2 subunits of AMPK in human embryonic kidney 293T cells by overexpressing AMPKα1 or α2 with and without SIRT2 co-overexpression. SIRT2 overexpression did not decrease the acetylation levels of AMPKα1 or AMPKα2 ( Figure VIII in the onlineonly Data Supplement), indicating that SIRT2 regulates AMPK activation indirectly.
Calcium/calmodulin-dependent protein kinase kinase β (CaMKKβ) and the LKB1 activate AMPK by phosphorylating Thr172 within the kinase domain of the α subunit. 10 We next investigated the potential participation of CaMKKβ in SIRT2-mediated activation of AMPK by inhibiting CaMKKβ using its inhibitor STO-609 (20 μM) in NRCMs. Indeed, STO-609 treatment reduced the phosphorylation of AMPK at Thr172 and the phosphorylation of ACC at Ser79. Interestingly, SIRT2 overexpression still increased AMPK and ACC phosphorylation in the presence of STO-609 ( Figure IXA in the online-only Data Supplement), indicating that CaMKKβ did not contribute to SIRT2-mediated activation of AMPK. Additionally, STO-609 alone increased cardiomyocyte size and promoted the expression of hypertrophic genes (Anp, Bnp, β-Mhc) in the model of Ang II-induced hypertrophy in NRCMs. However, STO-609 treatment did not block the effects of SIRT2 on cardiomyocyte size and the expression of hypertrophic genes in the NRCMs ( Figure IXB and C in the online-only Data Supplement). These results indicate that the effect of SIRT2 on AMPK activation is indirect and independent of CaMKKβ.
Next, the effect of SIRT2 on AMPK phosphorylation was analyzed in HeLa cells, which lack LKB1 as a result of promoter methylation.
28 SIRT2 overexpression did not promote AMPK phosphorylation in HeLa cells ( Figure  XA in the online-only Data Supplement). We also confirmed that adenovirus-mediated knockdown of Lkb1 in NRCMs reduced AMPK phosphorylation and blocked SIRT2-mediated activation of AMPK ( Figure XB in the online-only Data Supplement). Therefore, we further studied the possibility that SIRT2 regulates LKB1 activation. Sirt2-KO reduced the phosphorylation of LKB1 at Ser428 in aged and Ang II-induced hypertrophic hearts ( Figure 7A ). Conversely, cardiac-specific SIRT2 overexpression promoted LKB1 phosphorylation in Ang II-treated hearts ( Figure 7A ). SIRT2 also activated LKB1 in NRCMs because SIRT2 inhibitor AGK2 reduced the LKB1 phosphorylation and SIRT2 overexpression promoted LKB1 phosphorylation ( Figure XC in the onlineonly Data Supplement). In addition, the immunofluorescence assay demonstrated that SIRT2 overexpression significantly increased the cytosol-to-nucleus ratio of endogenous LKB1 in cardiomyocytes ( Figure 7B ). Therefore, these findings revealed that SIRT2 promotes the phosphorylation of LKB1 and facilitates its translocation to the cytoplasm, where it interacts with its partners (STRAD and MO25) to phosphorylate AMPK.
We next investigated whether SIRT2 regulates LKB1 activation directly. SIRT2 could interact with LKB1 when overexpressed in human embryonic kidney 293T cells ( Figure XIA in the online-only Data Supplement). We also found that the endogenous SIRT2 and LKB1 could interact with each other in cardiomyocytes ( Figure XIA in the online-only Data Supplement). We next investigated whether the deacetylase SIRT2 could deacetylate LKB1. SIRT2 overexpression reduced the acetylation levels of exogenous LKB1 in human embryonic kidney 293T cells. In addition, adenovirus-mediated SIRT2 overexpression also reduced the acetylation levels of endogenous LKB1 in NRCMs (Figure XIB in the onlineonly Data Supplement). Furthermore, Sirt2-KO significantly increased the acetylation levels of LKB1 in the aging-or Ang II-induced hypertrophic hearts, whereas opposing results were observed in Ang II-infused SIRT2-Tg hearts ( Figure 7C ). These findings strongly support the notion that SIRT2 binds to and deacetylates LKB1. Lysine 48 of LKB1 was reported to be the key lysine that determined the phosphorylation of LKB1 at Ser428. 29 We wanted to know whether lysine 48 is critical for the SIRT2-mediated deacetylation of LKB1 and the subsequent activation of LKB1 and AMPK. Therefore, lysine 48 of LKB1 was mutated to arginine 48 to generate a mutated LKB1 (LKB1 lysine-arginine 48) protein. Overexpression of SIRT2 did not change the acetylated level of LKB1 lysine-arginine 48 in human embryonic kidney 293T cells ( Figure XIC in the online-only Data Supplement), indicating that lysine 48 is the core target site for SIRT2. In addition, the lysine-arginine 48 mutant increased LKB1 and AMPK phosphorylation and blunted the effects of SIRT2 on LKB1 and AMPK phosphorylation ( Figure XID in the online-only Data Supplement). Therefore, SIRT2-mediated deacetylation of lysine 48 of LKB1 is critical for the activation of LKB1 and AMPK.
Finally, we investigated whether LKB1 is critically involved in SIRT2-mediated inhibition of hypertrophy in NRCMs. We knocked down Lkb1 in NRCMs with adenovirus and treated the cells with Ang II. Lkb1 knockdown promoted Ang II-induced increase in the size of NRCMs and expression of hypertrophic genes. Moreover, Lkb1 deficiency blocked SIRT2-mediated repression of cardiomyocyte hypertrophy and expression of hypertrophic genes in NRCMs (Figure 7D and E) . Taken together, these findings suggest that LKB1 is crucial for SIRT2-mediated repression of cardiomyocyte hypertrophy, which may be the mechanism underlying SIRT2-mediated cardioprotection against aging-and Ang IIinduced pathological cardiac hypertrophy.
SIRT2 Contributes to the Effects of Metformin on AMPK Activation and Cardiac Hypertrophy
Metformin is a first-line clinical drug for the treatment of diabetes mellitus, and it is associated with various cardiovascular benefits. AMPK is an important target for metformin and contributes to metformin-mediated cardioprotection. 13 We investigated whether AMPK activation by metformin could reduce the effects of Sirt2-KO on cardiac hypertrophy and subsequently rescue heart function.
We induced hypertrophy in WT and Sirt2-KO mice by infusing them with Ang II. The mice of each genotype were randomly divided into 2 groups and treated with metformin (200 mg/kg/d) or vehicle in drinking water for 4 weeks. Supplementation of metformin significantly activated AMPK in the heart tissues of WT mice. Interestingly, AMPK activation was blunted in the hearts of Sirt2-KO mice because metformin did not significantly upregulate AMPK phosphorylation in these mice ( Figure 8A ), indicating that SIRT2 is essential for metformin-mediated AMPK activation.
This surprising result prompted us to analyze the effects of metformin on cardiac function and pathological remodeling in WT and Sirt2-KO mice. Metformin treatment rescued the ejection fraction and fractional shortening of hypertrophic hearts in Ang II-infused WT mice ( Figure 8B ). In addition, the histochemical analysis showed that normalized heart weight, cardiomyocyte size, and cardiac fibrosis were reduced by metformin treatment in Ang II-infused WT mice ( Figure 8C-E) . However, the cardioprotective functions of metformin did not rely on its effect on heart rate and blood pressure because metformin did not affect heart rate or blood pressure in Ang II-infused WT mice ( Figure XIIA and B in the online-only Data Supplement). It is important to note that in Ang II-infused Sirt2-KO mice, metformin treatment did not rescue ejection fraction and fractional shortening ( Figure 8B ). The inhibitory effects of metformin on cardiac hypertrophy and fibrosis were also blunted by Sirt2-KO (Figure 8C-E) .
These results indicate that SIRT2 is essential for metformin-mediated activation of AMPK signaling and that SIRT2 contributes to the cardioprotective effects of metformin.
DISCUSSION
In the present study, we identified SIRT2 as a cardioprotective deacetylase in pathological cardiac hypertrophy. SIRT2 expression was decreased in hypertrophic hearts induced by aging and Ang II. Sirt2 deficiency promoted aging-related and Ang II-induced cardiac hypertrophy and led to a decline in cardiac function. Cardiac-specific SIRT2 transgene inhibited Ang II-induced cardiac hypertrophy and fibrosis and rescued cardiac function. The mechanistic study demonstrated that SIRT2 activated AMPK signaling by deacetylating and activating its upstream kinase LKB1, which contributed to the effects of SIRT2 on cardiac hypertrophy. In addition, Sirt2-KO repressed metformin-induced AMPK activation and blunted metformin-mediated cardioprotective functions.
Aging is one of the key risk factors for cardiac hypertrophy. 8 The Sirtuins modulate lifespan in species ranging from yeast to mammals.
14 In mammals, the Sirtuin family has 7 members with diverse cellular locations. Previous works from our group and others have reported the functions of Sirtuins (excluding SIRT2) in pathological cardiac hypertrophy. Although the roles of SIRT1 in pathological hypertrophy are still far from conclusive, all other Sirtuins (excluding SIRT4) are cardioprotective in cardiac hypertrophy. 18, 19, [30] [31] [32] [33] However, the roles of the Sirtuins in aging-related cardiac hypertrophy remain largely unknown. Genetic knockout of Sirt1, Sirt6, or Sirt7 leads to developmental defects and a premature reduction in lifespan (ranging from a usual survival of days [SIRT1] to weeks [SIRT6] or months [SIRT7]) in mice. [33] [34] [35] These facts make it difficult to investigate the functions of endogenous SIRT1/SIRT6/SIRT7 in agingdependent cardiac hypertrophy. We found that Sirt2-KO mice developed normally and could live for ≥2 years. Notably, these mice displayed more severe aging features (eg, hair browning) compared with WT mice at the late stage of life (24 months old). Interestingly, we observed that Sirt2 deficiency caused decreases in the ejection fraction and fractional shortening of aged mice. It is important to note that Sirt2-KO promoted aging-related increases in cardiomyocyte size and myocardial fibrosis. These findings suggest that Sirt2 deficiency facilitates aging-dependent cardiac hypertrophy. The concentration of Ang II is elevated in aged rodent hearts, and the activation of the renin-angiotensin system contributes to aging-dependent cardiac hypertrophy. 22 Ang II supplement could recur the development of cardiac hypertrophy observed in aged mice.
18 Sirt2-KO aggravated Ang II-induced cardiac hypertrophy and fibrosis and decreased ejection fraction and fractional shortening. It is important to note that SIRT2 protein levels and SIRT2 enzymatic activity levels were reduced in hypertrophic hearts. Therefore, loss of Sirt2 may be a mechanism that contributes to aging-related cardiac hypertrophy.
The mechanisms by which the Sirtuins participate in the pathogenesis of cardiac hypertrophy are much different from each other because of the difference in subcellular locations and primary enzymatic activities. SIRT1 is the most extensively studied among the Sirtuins in cardiac diseases. Low to moderate overexpression of SIRT1 in Tg mouse hearts represses oxidative stress and attenuates stress-induced cardiac hypertrophy, 19 whereas some studies reported that SIRT1 promotes the transition from hypertrophy to heart failure by promoting mitochondrial dysfunction or activating the Akt signaling. 36, 37 In the mitochondria, SIRT3 participates in pathological hypertrophy by activating forkhead box O3a and manganese-dependent superoxide dismutase to repress oxidative stress, whereas SIRT4 represses the SIRT3-manganese-dependent superoxide dismutase pathway and promotes stressinduced cardiac hypertrophy. 18, 30, 38 Mice with Sirt5 deficiency develop hypertrophic cardiomyopathy in ≤9 months partially because of a metabolic defect. 32 In the nucleus, SIRT6 regulates IGF-Akt signaling and represses stress-induced cardiac hypertrophy, whereas Sirt7-KO leads to apoptosis and hypertrophy of cardiomyocytes. 31, 33 Differently, SIRT2 is predominantly located in the cytosol and deacetylates LKB1 to activate AMPK and subsequently repress pathological cardiac hypertrophy. Sirt2 deficiency reduced AMPK phosphorylation but did not alter SIRT1 expression or IGF1R phosphorylation in aged hearts. SIRT2-mediated activation of AMPK signaling was confirmed in the hearts of Ang II-treated Sirt2-KO mice and NRCMs with SIRT2 inhibition. In contrast, SIRT2 overexpression in hearts and NRCMs could activate AMPK signaling. Significantly, SIRT2-mediated AMPK activation contributed to the inhibitory effects of SIRT2 on Ang II-induced cardiomyocyte hypertrophy. AMPK activation is impaired in aged murine hearts compared with young murine hearts, 39 and AMPK deficiency promoted aging-related cardiac hypertrophy. 12 Our results showed that the SIRT2 expression was decreased in aged and Ang II-induced hypertrophic hearts. Therefore, the repressed AMPK activation in aged hearts may be a result of the reduced SIRT2 protein levels. AMPK activation is a core contributor to metformin-mediated cardioprotective functions. 13 It is important to note that metformin-mediated activation of AMPK in hypertrophic hearts was also repressed by Sirt2 deficiency. These findings support the notion that SIRT2 is essential for AMPK activation in myocardial tissues.
When activated by phosphorylation, LKB1 translocates from the nucleus to the cytoplasm and phosphorylates its substrates such as AMPK.
9 LKB1 is the major upstream kinase of AMPK, and LKB1 mediates AMPKα2 phosphorylation in the cardiac tissues. 9 Cardiomyocyte-specific KO of Lkb1 would cause cardiac hypertrophy through the inhibition of AMPK signaling and activation of mTOR signaling in mice. 40 However, the upstream regulators of LKB1 in the cardiac tissues are largely unknown. Our findings demonstrate that SIRT2 serves as an upstream activator of LKB1. Sirt2 deficiency reduced LKB1 phosphorylation in aged and Ang II-induced hypertrophic hearts, whereas SIRT2 overexpression increased LKB1 phosphorylation in hypertrophic hearts. Additionally, SIRT2 promoted the translocation of LKB1 from the nucleus to the cytoplasm, where it cooperates with its partners to phosphorylate AMPK at Thr172. SIRT2-mediated LKB1 activation relies on LKB1 deacetylation. LKB1 could interact with SIRT2, which made it possible for SIRT2 to deacetylate LKB1 in cardiomyocytes and myocardial tissues. SIRT2 deacetylates LKB1 at lysine 48, which is critical for LKB1 phosphorylation and translocation. 29 Mutation of LKB1 at lysine 48 to arginine 48 activated LKB1 and its downstream substrate AMPK and blocked the effect of SIRT2 on LKB1 and AMPK activation. It is important to note that LKB1 contributes to SIRT2-mediated inhibition of cardiac hypertrophy. Although the Sirtuins share some substrates, their affinity and deacetylation efficiency are much different. Indeed, SIRT1 was also reported to deacetylate LKB1 and activate AMPK in cells. 29 However, a later report using in vitro acetylome peptide microarray revealed that the deacetylation efficiency of SIRT1 at lysine 48 (and some other lysine sites) of LKB1 is much lower than that of SIRT2. 41 Additionally, an in vitro deacetylation assay also showed that SIRT1 seemed not to deacetylate the LKB1 peptide containing acetylated lysine 48.
42 SIRT1 may regulate AMPK by other mechanisms. For instance, SIRT1 regulates secretion of adipokines such as adiponectin, 43 which activates AMPK in a CaMKKβ-dependent manner. 44 Our findings support that SIRT2 may be the primary direct deacetylase for LKB1 and that SIRT2 activates AMPK depending on LKB1 but not CaMKKβ. In this regard, SIRT1 and SIRT2 may activate AMPK through different mechanisms.
In addition to the LKB1-AMPK signaling, some other mechanisms may also contribute to SIRT2-mediated cardioprotective functions. For instance, SIRT2 exerts effects on microtubule stabilization via Tubulin deacetylation and on oxidative stress via forkhead box O3a signaling. Both mechanisms are involved in hypertrophy pathogenesis. 45, 46 Some other targets of SIRT2, such as forkhead box O1 and peroxisome proliferator-activated receptor gamma coactivator-1 alpha, are also known regulators for cardiac hypertrophy. 11, 17 It is interesting to note that most of these factors (Tubulin, forkhead box O1, forkhead box O3a, and peroxisome proliferatoractivated receptor gamma coactivator-1 alpha) are also downstream of the LKB1-AMPK signaling. 11, 45 Therefore, activation of the LKB1-AMPK signaling may be a core mechanism underlying SIRT2-mediated cardioprotective functions.
Metformin is a first-line antidiabetic drug, which also reduces mortality and readmission in patients with heart failure. 47 AMPK is the major target of metformin. AMPK activation by metformin represses cardiac remodeling and rescues cardiac function in aging and stress-induced hypertrophy and ischemia-induced cardiac injury in rodents and dogs. 12, [48] [49] [50] Metformin activates AMPK through LKB1-dependent mechanisms.
13 Sirt2 deficiency repressed metformin-mediated AMPK activation, which may be because of repressed LKB1 activation in Sirt2-deficient hearts. Currently, clinical trials studying the therapeutic effects of metformin on longevity (ClinicalTrials.gov. Unique identifier: NCT02432287) and ventricular hypertrophy (ClinicalTrials.gov. Unique identifiers: NCT02226510, NCT01879293) are ongoing. Our results showed that SIRT2 expression was decreased in hypertrophic hearts and that the cardioprotective effects of metformin were significantly abolished in Sirt2-KO mice. Therefore, SIRT2 expression should be considered in future trials of metformin therapies in patients with cardiac hypertrophy and heart failure.
In conclusion, we identify SIRT2 as a cardioprotective deacetylase. SIRT2 prevents aging-dependent and Ang II-induced pathological hypertrophy by maintaining cardiac LKB1-AMPK signaling. These findings improve our understanding of aging-dependent and stress-induced pathological cardiac hypertrophy and indicate that SIRT2 is a potential target for therapeutic interventions for pathological cardiac hypertrophy.
